SCHEMBL5483211

SCHEMBL5483211

O=C1Nc2ccc(-c3ccncc3)cc2C1(c1ccc(O)cc1)c1ccc(O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.55
ADORA3 P0DMS8 1/20 0.55
KCNH2 Q12809 1/20 0.55
PDE3B Q13370 3/20 0.43
PDE3A Q14432 3/20 0.43
CNR1 P21554 1/20 0.41
HTT P42858 1/20 0.41
GPR35 Q9HC97 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
XBP1 P17861 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
OTUD7B Q6GQQ9 1/20 0.39
QDPR P09417 1/20 0.38
CDC7 O00311 1/20 0.38
ROCK2 O75116 1/20 0.38
MAP4K4 O95819 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5483371 0.86 CHRM2 (0.66) CHRM2ADORA3KCNH2CNR1HTT
SCHEMBL5480079 0.79 CHRM2 (0.62) CHRM2ADORA3KCNH2CNR1HTT
SCHEMBL5477966 0.78 KCNH2 (0.55) CHRM2ADORA3KCNH2CNR1HTT
SCHEMBL5478164 0.76 CHRM2 (0.62) CHRM2ADORA3KCNH2CNR1HTT
SCHEMBL5481309 0.76 CHRM2 (0.62) CHRM2ADORA3KCNH2CNR1HTT
SCHEMBL5483163 0.76 CHRM2 (0.62) CHRM2ADORA3KCNH2CNR1HTT
SCHEMBL5479245 0.76 CHRM2 (0.62) CHRM2ADORA3KCNH2CNR1HTT
SCHEMBL5483481 0.76 CHRM2 (0.62) CHRM2ADORA3KCNH2CNR1HTT
SCHEMBL5486582 0.76 CHRM2 (0.62) CHRM2ADORA3KCNH2CNR1HTT
SCHEMBL13145364 0.74 CHRM2 (0.85) CHRM2ADORA3KCNH2CNR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 CHRM2 2994/4885ADORA3 3566/4885KCNH2 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.